Abstract:As one of the most common breast cancer subtypes, luminal A breast cancer is sensitive to endocrine-based therapy and insensitive to chemotherapy. Patients with luminal A subtype of breast cancer have a relatively good prognosis compared with that of patients with other subtypes of breast cancer. However, with the increased incidence in endocrine resistance and severe side effects, simple endocrine therapy has become unsuitable for the treatment of luminal A breast cancer. Therefore, identifying novel therapeutic targets for luminal A breast cancer may accelerate the development of an effective therapeutic strategy. The bioinformatical analysis of the current study, which included KEGG and GO analyses of the GSE20437 dataset containing 24 healthy and 18 breast cancer tissue samples, identified key target genes associated with breast cancer. Moreover, survival analysis results revealed that a low expression of BTG2 was significantly associated with the low survival rate of patients with breast cancer, indicated that B-cell translocation gene 2 (BTG2) may be a potential target in breast cancer. However, BTG2 may be cancer type-dependent, as overexpression of BTG2 has been demonstrated to suppress the proliferation of pancreatic and lung cancer cells, but promote the proliferation of bladder cancer cells. Since the association between BTG2 and luminal A-subtype breast cancer remains unclear, it is important to understand the biological function of BTG2 in luminal A breast cancer. Based on the expression levels of estrogen receptor, progesterone receptor and human epidermal growth factor receptor, MCF-7 cells were selected in the present study as a luminal A breast cancer cell type. MTT, Transwell invasion and wound healing assays revealed that overexpression of BTG2 suppressed the levels of MCF-7 cell proliferation, migration and invasion. In addition, the downregulation of BTG2 at the mRNA and protein level was also confirmed in luminal A breast tumor tissue, which was consistent with the results in vitro. These results indicated that BTG2 may act as an effective target for the treatment of luminal A breast cancer.

B-Cell Translocation Gene 2 Upregulation is Associated with Favorable Prognosis in Lung Adenocarcinoma and Prolonged Patient Survival

Expression of B-cell Translocation Gene 2 is Associated with Favorable Prognosis in Hepatocellular Carcinoma Patients and Sensitizes Irradiation-Induced Hepatocellular Carcinoma Cell Apoptosis in Vitro and in Nude Mice.

BTG2 and SerpinB5, a novel gene pair to evaluate the prognosis of lung adenocarcinoma

Overexpressed BSG Related to the Progression of Lung Adenocarcinoma with High-Throughput Data-Mining, Immunohistochemistry, in Vitro Validation and in Silico Investigation.

P3.16-01 A Multi-Omic Study Reveals BTG2 As a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer

BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo.

Role of BAG2 gene in A549 cell proliferation and its clinical implications

Effect of B-cell Translocation Gene 2 Alteration on Radiosensitivity of Cancer Cells

SGO2 as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma

SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression

BTG2 Suppresses the Growth and Metastasis of Cervical Squamous Cell Carcinoma

TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.

BTG2 As a Tumor Target for the Treatment of Luminal A Breast Cancer

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis

Transcriptomic Analyses Reveal B-Cell Translocation Gene 2 as a Potential Therapeutic Target in Ovarian Cancer

ADRB2 expression predicts the clinical outcomes and is associated with immune cells infiltration in lung adenocarcinoma

NCAPG2 Promotes Tumour Proliferation by Regulating G2/M Phase and Associates with Poor Prognosis in Lung Adenocarcinoma

Bioinformatics and integrated analyses of prognosis-associated key genes in lung adenocarcinoma

Identification ofLBX2as a novel causal gene of lung adenocarcinoma

TPD52L2 is a Prognostic Biomarker and Correlated with Immune Infiltration in Lung Adenocarcinoma

BTG2 Inhibits the Proliferation, Invasion, and Apoptosis of MDA-MB-231 Triple-Negative Breast Cancer Cells